Background The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With
Factor Xa Next Generation in
Atrial Fibrillation-Thrombolysis in
Myocardial Infarction 48) demonstrated noninferiority of once-daily 60 mg (30 mg dose-reduced)
edoxaban compared with
warfarin for prevention of
stroke/systemic
embolism in patients with
atrial fibrillation. No previous analysis has explored the impact of treatment with
edoxaban versus
warfarin on rates of hospitalizations. Methods Detailed healthcare resource utilization data from ENGAGE AF-TIMI 48 for the 14 024 randomized patients who received at least one dose of study drug were used to compare the rates of
bleeding- and cardiovascular-related hospitalizations for
edoxaban versus
warfarin. Hospitalization rates were calculated for each treatment group, and relative rates were estimated using Poisson regression. The influence of patient characteristics on the impact of
edoxaban versus
warfarin was evaluated through the inclusion of interaction terms. Results The overall rate of cardiovascular- or
bleeding-related hospitalization was significantly lower for
edoxaban than
warfarin (relative rate [RR], 0.91 [95% CI, 0.85-0.97], P=0.003). Rates of hospitalizations for cardiovascular reasons (RR, 0.91 [95% CI, 0.85-0.97], P=0.004),
stroke (RR, 0.80 [95% CI, 0.72-0.88], P<0.0001), and for each
stroke subtype (ischemic: RR, 0.89 [95% CI, 0.81-0.99], P=0.03; hemorrhagic: RR, 0.60 [95% CI, 0.54-0.68], P<0.0001) were also lower for
edoxaban. Notably, significantly greater reductions with
edoxaban versus
warfarin were seen for
ischemic stroke-related hospitalizations in
vitamin K antagonist naive patients and patients with CHADS2 scores 4 to 6, previous
stroke or
transient ischemic attack, age ≥75, and no previous
coronary artery disease. For nonstroke
bleeding-related hospitalizations, greater reductions with
edoxaban were seen in
vitamin K antagonist naive patients, patients with CHADS2 scores 4 to 6, and patients with moderate renal dysfunction. Conclusions
Edoxaban 60 mg (30 mg dose-reduced) was associated with a significantly lower overall rate of cardiovascular- or
bleeding-related hospitalization and significant reductions in the subcategories of cardiovascular-related,
stroke-related, bleed-related, and nonstroke cardiovascular-related hospitalizations, when compared with
warfarin. These results suggest the potential for cost offsets with
edoxaban, with even greater reductions in higher-risk patients. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00781391.